EP1263936B1 - Altered strain of the modified vaccinia virus ankara (mva) - Google Patents
Altered strain of the modified vaccinia virus ankara (mva) Download PDFInfo
- Publication number
- EP1263936B1 EP1263936B1 EP01931508A EP01931508A EP1263936B1 EP 1263936 B1 EP1263936 B1 EP 1263936B1 EP 01931508 A EP01931508 A EP 01931508A EP 01931508 A EP01931508 A EP 01931508A EP 1263936 B1 EP1263936 B1 EP 1263936B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mva
- cells
- vero
- cell line
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/08—Inactivation or attenuation by serial passage of virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
Definitions
- the present invention relates to new strains of the Modified Vaccinia virus Ankara (MVA) that have a strongly reduced virulence for most mammals, especially humans, but nevertheless grows in cells of a continuous cell line approved for the production of a therapeutic agent such as a vaccine.
- the invention also relates to a method for producing said adapted MVA strains.
- the MVA can be used e.g. for parenteral immunization, as a vector system, or in the active or inactivated form as an adjuvant or as a regulator of the unspecific components of the immune system.
- An organism is constantly challenged by infectious agents like bacteria, viruses, fungi or parasites.
- the immune system prevents the organism from permanent infection caused by these agents by the destruction and elimination of these infectious agents and any toxic molecules produced by them.
- the immune system can be divided into a specific and an unspecific part although both parts are closely cross linked.
- the unspecific immune response enables an immediate defense against a wide variety of foreign substances and infectious agents.
- the specific immune response is raised after a lag phase, when the organism is challenged with a substance for the first time.
- the specific immune response is highly efficient.
- the specific immune response is responsible for the fact that an individual who recovers from a specific infection is protected against this specific infection but still susceptible for other infectious diseases.
- a second infection with the same or a very similar infectious agent causes much milder symptoms or no symptoms at all.
- the immunity persists for a long time, in some cases even lifelong.
- This immunological memory is used for vaccination, where the organism is challenged with a harmless or inactivated form of the infectious agent to induce a specific immunity.
- adjuvants are incorporated into vaccines to enhance the specific immune response.
- the pox vaccine consists of the pox virus Modified Vaccinia Virus Ankara (MVA) and was used for parenteral vaccination against smallpox in about 150 000 vaccinations without causing any complications related to the vaccination. Even children with immunologic deficiencies did not show serious side effects.
- the MVA was obtained by mutation and selection of the original vaccina virus Ankara after 575 passages in chicken embryo fibroblast cultures. The safety of this MVA is reflected by biological, chemical and physical characteristics. MVA has a reduced molecular weight, six deletions in the genome, and is highly attenuated for mammalian cells, i.e. DNA and protein is synthesized but virtually no viral particles are produced.
- the Modified Vaccina virus Ankara developed by Anton Mayr was deposited at the European Collection of Cell Cultures (ECACC), Salisbury, UK, under depository No. V 94012707.
- the MVA may be of significance as a vector for gene therapy, i.e. to transfer nucleic acid sequences into a target cell where they are expressed.
- the host ranges of MVA and of the parental Ankara strain were compared in chicken embryo fibroblast (CEF) cells and 15 permanent cell lines (Carroll, M.W. and Moss, B. (1997): Virology 238, 198-211).
- the cells were grouped into three categories: permissive, semipermissive, and nonpermissive. It was found that baby hamster kidney (BHK) cells supported MVA growth and that only in this cell line did the virus yield approach that occurring in primary CEF cells. Other cell lines were non-permissive or allowed only limited MVA replication.
- the permissive BHK cell line was shown to be also competent for constructing and propagating recombinant MVA, providing an alternative to primary CEF.
- cell cultures of primary or secondary chicken embryo fibroblasts are used.
- the cells are obtained from chicken eggs that are incubated for 10 to 12 days. Since eggs are subjected to a biological variability, the cells obtained for the cell culture system are variable on a cellular level as well.
- fibroblast culture often other cell types such as epithelial cells are found. This variation of the cells also results in variation of viruses produced in chicken embryo fibroblasts. It is therefore difficult to standardize and validate the cell culture system to guarantee a constantly high quality of the MVA produced. Furthermore, contamination of the cell culture system by microorganisms or viruses already present in the incubated eggs can not be completely excluded.
- the MVA When the MVA is grown in virus-contaminated cells, the MVA may recombine with the contaminating virus. Thereby an MVA with new and unpredictable characteristics may be generated.
- primary or secondary chicken embryo fibroblasts are also not highly suitable.
- the purification and concentration of MVA by ultra gradient centrifugation would be advantageous. However, such purification is difficult, when MVA is cultivated on primary or secondary chicken embryo fibroblast.
- an increasing number of patients have developed allergies against chicken egg's albumen. Although the in vitro conditions of the cultivation strongly reduce the allergenic potential, a hazard of an allergic reaction can not be completely excluded.
- the MVA can only be efficiently grown in primary or secondary chicken embryo fibroblasts causing a number of disadvantages, however, on the other hand the save application of the MVA in humans has been shown by its large-scale application as a vaccine.
- the invention inter alia comprises the following, alone or in combination:
- a modified vaccinia virus Ankara adapted for growing in cells of a Vero cell line, obtainable by a process comprising the steps of: a) infecting cells of the Vero cell line with a wild-type MVA, preferably with the MVA deposited at the European Collection of Cell Culture (ECACC), Salisbury, UK, under depositary No. V94012707; b) harvesting the viral particles produced by the infected cells of said cell line; and, c) infecting fresh cells of the Vero cell line with the newly produced viruses and harvesting the virus produced from said cells, wherein step c) is repeated until the Output/Input ratio of the virus titer is greater than 1.
- ECACC European Collection of Cell Culture
- ECACC European Collection of Cell Cultures
- Salisbury UK under depositary No. 99101431
- Ankara adapted for growing in Vero cells at a rate which is the same as the growth rate of the deposited strain, but which carries at least one difference in its genome.
- ECACC European Collection of Cell Cultures
- Salisbury UK
- depositary number 01021411 a modified vaccinia virus Ankara adapted for growing in Vero cells at a rate which is the same as the growth rate of the deposited strain, but which carries at least one difference in its genome.
- the MVA as above comprising at least one heterologous nucleic acid sequence.
- heterologous nucleic acid sequence codes for a therapeutic protein and/or an antigenic determinant.
- a host cell infected in vitro or ex vivo by the above described MVA A host cell infected in vitro or ex vivo by the above described MVA.
- composition preferably a pharmaceutical composition, comprising the above described MVA and/or the DNA of the MVA.
- composition described above wherein the composition is a vaccine.
- composition described above for the immunization of a living animal body including a human The composition described above for the immunization of a living animal body including a human.
- composition as above for the immunization against an Orthopox infection The composition as above for the immunization against an Orthopox infection.
- composition as above for the immunization of cats against a cat pox infection, mice against ectromelia infection and/or camels against camelpox infection are provided.
- composition described above wherein the MVA is an activator, suppressor and/or stabilizer of the immune system.
- composition preferably a pharmaceutical composition, comprising the above described MVA and/or the DNA of the MVA as an adjuvant.
- a composition preferably a pharmaceutical composition, comprising the above described recombinant MVA and/or the DNA of the recombinant MVA for use in gene therapy.
- a method for introducing a homologous and/or heterologous nucleic acid sequence into a target cell in vitro or ex vivo comprising infecting the target cell with the above described MVA and/or DNA of the MVA.
- a method for obtaining an MVA strain as described above comprising the steps of: a) infecting cells of a Vero cell line with a wild-type MVA, preferably the MVA deposited at ECACC under depository No. V 94012707, b) harvesting the viruses obtained from the cells infected according to step a), c) infecting fresh cells of the Vero cell line with the newly produced viruses and harvesting the virus produced from said cells, wherein step c) is repeated until the Output/Input ratio in viral titer is greater than 1.
- a method for producing viral particles of the above described MVA comprising the steps of: a) cultivating the cells of a cell line, in which the MVA replicates under suitable conditions, b) infecting said cell line with the MVA as described above, and c) harvesting the viral particles produced by said cells.
- a method for producing a nucleic acid sequence, peptide and/or polypeptide comprising the steps of: a) infecting a host cell with the above described recombinant MVA, b) cultivating the infected host cell under suitable conditions, and, optionally, c) isolating and/or enriching the nucleic acid sequence, peptide and/or protein produced by said host cell.
- the present invention provides an MVA strain that is adapted for growing in cells of a continuous cell line, namely in a Vero cell line, said cell line being approved for the production of a therapeutic agent.
- the present invention for the first time an efficient and large-scale production of MVA is possible. Since cells of a continuous cell line are homogeneous and their characteristics are stable the MVA harvested from Vero cell lines is also homogeneous with highly predictable characteristics. Furthermore, the risk of contamination by microorganisms can be controlled and contamination of the MVA preparation by proteins of the chicken egg as found when cultivating MVA on chicken embryo fibroblasts - can be excluded. The handling of a permanent cell line is convenient and thus highly suitable for industrial application.
- the MVA is adapted for growing in cells of a mammalian cell line, which is approved for the production of a vaccine. It has been surprisingly found that the MVA adapted to this mammalian cell line still has a reduced virulence for humans and also for a wide range of other mammals. Accordingly, the MVA is highly attenuated i.e. DNA and protein is synthesized but virtually no viral particles are produced, resulting in a virtually eliminated disease-causing capacity. Hence, the MVA according to the present invention is also highly suitable as a vaccine for humans and for a wide range of mammals. Accordingly, the MVA is especially applicable in the veterinary field.
- an MVA strain according to the present invention.
- cells of a Vero cell line are infected with the wild-type MVA.
- MOI multiplicity of infection
- the viruses are harvested and fresh cells of the same cell line are infected with the newly produced viruses. Said process is repeated (serial passaging) until the MVA is adapted to said cell line.
- the virus titer is at least 1 ⁇ to 9-fold, preferably 10 ⁇ to 99-fold, more preferably 100- to 10 6 -fold, and most preferably more than 10 7 ⁇ to 10 10 ⁇ fold increased compared to the input virus titer.
- the adaptation is reached after a limited number of passages.
- Adapted for growing means that the amount of virus produced from an infection (Output) is increased compared to the amount of virus originally used to infect the cells (Input). In this case the Output/Input ratio is greater than 1.
- Derivative of the MVA deposited at ECACC, Salisbury, UK, under the depository number 99101431 and/or accession number 01021411 means an MVA which is adapted for growing in Vero cells at a rate, which is essentially the same as the growth rate of the deposited strain but carries at least one difference in its genome compared to the deposited strain.
- immune system basically describes a complex involved in the defence of the organism against foreign substances and microorganisms. It is divided into a cellular part comprising several cell types, such as e.g. lymphocytes and other cells derived from white blood cells, and a humoral part comprising peptides and proteins such as antibodies, complement factors, and cytokins.
- immune response describes the reaction of the immune system, when a foreign substance or microorganism enters the organism. Generally, the immune response is divided into a specific and an unspecific reaction although both are closely cross linked. The unspecific immune response is regarded as the immediate defence against a wide variety of foreign substances and infectious agents.
- the specific immune response can be characterised as a highly efficient defence mechanism of the organism against a foreign substance which is raised against said substance after a lag phase and highly specific for said substance. The specific immune response is responsible for the phenomenon that an individual who has recovered from a specific infection is protected against this specific infection in future.
- Activator of the immune system means any substance capable of provoking or enhancing an immune response.
- “Suppressor of the immune system” means any substance capable of reducing or inhibiting an immune response.
- Stabilizer of the immune system means any substance capable of keeping the immune response on a constant level.
- the inventor provides two preferred MVA strains that are adapted to an African green monkey cell line, called Vero cell line (ATCC No. CCL-81).
- the MVA-strain which was passaged 100-times in Vero cells was called “Vero-MVA” and deposited at the European Collection of Cell Cultures, Salisbury, UK under depositary No. 99101431.
- the MVA strain after 200 passages in Vero cells was called “Vero-MVA-200" and deposited at ECACC under accession number 01021411.
- the MVA obtained as described above is further amplified by cultivating the cells of the approved cell line under suitable conditions, infecting cells with the MVA and harvesting the viral particles produced by said cells.
- the MVA can efficiently and easily be amplified in large-scale.
- the MVA of the invention does not show increased virulence in cells other than Vero cells such as human cell lines including HL, HEP-2 or HeLA.
- the MVA contains at least one heterologous nucleic acid sequence i.e. a nucleic acid sequence that is not naturally found in the MVA genome (recombinant MVA).
- the heterologous nucleic acid sequence is a gene, more preferably a gene encoding an immunizing protein, and most preferably encoding a protein immunizing against malaria, rabies and/or hepatitis.
- the expression of said heterologous nucleic acid sequence is preferably under the transciptional control of a vaccinia virus promoter, more preferably of an MVA-own promoter.
- the heterologous nucleic acid sequence is inserted at a naturally occurring deletion site in the MVA genome (disclosed in PCT/EP96/02926).
- the recombinant MVA is used for the introduction of a nucleic acid sequence into a target cell, said nucleic acid sequence being homologous or heterologous to the target cell.
- the introduction of a heterologous nucleic acid sequence into a target cell may be used to produce heterologous nucleic acids, peptides and/or polypeptides and/or proteins encoded by said nucleic acid sequence in vitro.
- This method comprises the infection of a host cell with the recombinant MVA, cultivation of the infected host cell under suitable conditions, and optionally isolation and/or enrichment of the peptide and/or protein produced by said host cell.
- the introduction of a homologous or of a heterologous sequence may be applied for in vitro and in vivo gene therapy.
- cells are isolated from the individual to be treated, transformed with the recombinant MVA and reintroduced into the individual the cells were taken from.
- the recombinant MVA is directly administered to the living animal body including the human body.
- the recombinant MVA expresses an antigen or an antigenic epitope.
- said vector expresses an antigenic determinant from Plasmodium falciparum, Mycobacteria, Herpes virus, Influenza virus, hepatitis, or a human immunodeficiency virus.
- the present invention also provides a vaccine comprising the MVA for the immunization of a living animal body including a human against pox infections, preferably orthopox infections.
- the vaccine may contain in addition to the MVA one or more additives such as an antibiotic, a preservative, or a stabilizer.
- the vaccine is especially applicable in the veterinary field, e.g. for the immunization of animals against orthopox infections such as cats against cat pox, mice against ectromelia or camels against camelpox.
- the immunization is preferably performed parenterally.
- the immunizing effect of an antigenic determinant in a vaccine is often enhanced by the addition of a so-called adjuvant.
- An adjuvant co-stimulates the immune system in an unspecific manner causing a stronger specific immune reaction against the antigenic determinant of the vaccine.
- the MVA is used as an adjuvant, to co-stimulate the immune response against the antigenic determinant of a vaccine.
- the MVA is inactivated.
- the inactivation of the MVA may be performed e.g. by heat or chemicals.
- the MVA is inactivated by ⁇ -propiolacton.
- the inactivated MVA may be added to vaccines against numerous infectious diseases to increase the immunity against this disease.
- the immune, the nervous, the hormonal and the vascular system of an individual work closely together. These interactions can be regulated by elements of the unspecific immune system e.g. cytokines such as interferons and interleukins. Pox viruses can influence the regulation of the immune system (Swiss Vet 11/99, 13-17).
- the MVA and preferably the inactivated MVA is used in mammals including humans to regulate the cellular and humoral elements of the unspecific (innate) immune system.
- the MVA is used as a bioregulator, wherein dysfunctions of the immune system are eliminated and the body's own defence mechanisms are activated, stabilized and/or suppressed.
- the MVA is used as a bioregulator in case of a viral infection e.g. with herpes, hepatitis B or C virus, in case of a chronic inflammatory disease and/or to support tumor therapy.
- the MVA may also be used to stabilize the immune system in a situation of increased susceptibility against infections such as in the case of stress or in neonatals.
- the active and/or preferably the inactivated MVA can be applied systemically e.g. intramuscularly and/or locally e.g. through mucous membranes and/or skin.
- the present invention provides MVA strains that can in general be used for the same applications as the wild-type MVA, but eliminate the problems caused by the amplification of the wild-type MVA in chicken embryo fibroblasts.
- the wild-type MVA was adapted to grow in Vero-cells by serial passaging of the virus in Vero cells (Table 1).
- the cell clone ATCC-No. CCL-81 of the stationary Vero cell line (WHO seed stock ECACC No. 88020401) was used in the passage No. 148 to 165 (WHO seed lot, Master and Working Bank).
- the cells were propagated in a medium consisting of Earle's MEM (ICN), pH 7,4 - 7,6, and 5% of the serum substitute BMS (Biochrom).
- the same cells of the working bank were seeded by splitting the cells 1:2 to 1:4.
- the medium contained approximately 250 000 cells per ml.
- the cells were respectively propagated in tubes (2ml), Roux dishes (100ml), and plastic dishes (6 and 40ml respectively).
- the cells formed a confluent monolayer after 16 to 24h. Afterwards, the medium was replaced by plain Earle's MEM without any additives.
- the results of the passages are summarized in Table 1 and 2.
- the Vero cells were infected by 10 MOI (multiplicity of infection) of the wild-type MVA, i.e. in average, 10 viral particles per Vero cell.
- the wild-type MVA to start with was a genetically homogeneous, plaque-purified MVA after 575 passages in chicken embryo fibroblasts (titer: 10 7,75 KID 50 /ml). After 24h, 90% of the Vero cells of the confluent monolayer were destroyed by toxic processes (50% by toxicity, 40% by lysis).
- CPE cytopathic effect
- the virus titer increased from 10 1,0 KID 50 /ml after the third passage to 10 4,0 KID 50 /ml after the fifth passage. Hence, the virus amplified more efficiently in Vero cells.
- a complete CPE was observed more and more early and the virus titer increased with every passage.
- a plateau was reached at 10 7,5 KID 50 /ml. Accordingly, after eleven passages the adaptation of the MVA to Vero cells was achieved.
- the results were for all passages the same and highly reproducible: The CPE began already 24h p.inf. and all cells were affected after three days p. inf.
- the virus titer was always about 10 7,75 KID 50 /ml.
- the viruses were always harvested after two to three days p.inf., and only 1 MOI instead of 10 MOI were used to infect the cells (Table 2).
- the growth characteristics of the MVA changed only slightly. Remarkably, the optimum virus titer further increased and reached 10 10 KID 50 /ml at passage 200.
- the virus grows reproducibly in an exponential manner in Vero cells. Said growth characteristic is surprisingly different to the characteristics of the wild-type MVA. Accordingly, a new strain of the MVA was obtained by the serial passaging. Said new strain was called “Vero-MVA” and after passage 200 in vero cells "Vero-MVA-200".
- the Vero-MVA and Vero-MVA-200 were cultivated in larger quantities. For storage, the Vero-MVA was concentrated by centrifugation, resuspended in 2,5 % polygeline and lyophilized in vials of 2ml. The titer after lyophilization was still at least 10 8,5 KID 50 /ml. The lyophilized Vero-MVA and Vero-MVA-200 was checked for contamination and toxicity and stored at +4°C.
- Vero-MVA The biological characteristics of the Vero-MVA (passage 100) and Vero-MVA-200 (passage 200) were compared with the characteristics of the wild-type MVA (Table 3 and Table 5). Thereby, the techniques known by the skilled practitioner were applied. The inventors showed that neither the host range of the virus was changed except for the Vero cells, nor the virulence for humans or animals was increased. The Vero-MVA is still characterized by the abortive propagation in non-permissive host cells.
- the principal identity of the viral particles of the Vero-MVA compared to the viral particles of the Elstree strain of the Vaccinia virus was shown by cross reactivity of antibodies raised against the Elstree strain.
- the Elstree strain is a Vaccinia strain recommended by the WHO for the smallpox vaccination.
- the polyclonal hyperimmune serum of rabbits raised against the Elstree strain was added to the Vero-MVA. 100 KID 50 /ml of the Vero MVA were completely neutralized at a dilution of the serum of 1:512. A twofold dilution of the serum was necessary to neutralize the same amount of Vaccinia Elstree strain (1:256). Accordingly, the Vero-MVA can still be efficiently neutralized by Vaccinia immune serum.
- the Vero-MVA, the Vero-MVA-200 and the wild-type MVA were compared by a number of additional tests as indicated in Table 3, 4 and 5.
- the inventors showed that the virulence of Vero-MVA and Vero-MVA-200 for mammals including humans was not increased compared to the wild-type MVA. It was also shown that the Vero-MVA and Vero-MVA-200 are not contagious or toxic for mammals including humans.
- the cell specificity of the Vero-MVA was more or less identical to the specificity of the wild-type MVA except for the Vero cells:
- the Vero-MVA amplifies nearly as inefficiently in cells of human cell lines (see table 4: HL-, HEP-2-, and HeLa-cells) as the wild-type MVA does. Accordingly, although human cells and cells of African green monkeys are phylogenetically closely related, the Vero-MVA did not gain the ability to amplify in human cells. In other tests, no significant difference were seen either.
- the physical, chemical, and biological characteristics of the wild-type MVA and the Vero-MVA-200 were compared (Table 5). Whereas the wild-type MVA growing in chicken embryo fibroblast cell cultures has three deletions in the left inverted terminal region, the Vero-MVA-200 has four deletions in the left terminal region compared to the genome of the pox virus as originally isolated in Ankara. Hence, passaging of the wild-type MVA in Vero cells resulted in an additional deletion.
- the Vero-MVA was used to immunize domestic animals against Orthopox infections.
- the serum of the animals was collected and a neutralization test was performed.
- the inventors showed that the animals produced antibodies in high titers.
- the antibody titers were stable over a period of at least 111 days. It was also shown that the antibodies were able to neutralize in vitro viral particles of the MVA in a plaque-reduction test.
- the Vero-MVA can be used as a vaccine against Orthopox infections in domestic animals and in humans.
- Table 1 Adaptation of the MVA to Vero cells Passage No.
- Table 2 Change of the virus titers during the adaptation of the MVA to Vero cells Passage No. Harvested after [days p.inf.] Titer per ml [log 10 /ml] 1 1 ⁇ 2,0 2 3 2,0 3 5 1,0 5 5 4,0 8 4 6,5 11 3 7,5 18 2 8,0 19 2 7,75 20 3 8,0 25 2 7,75 29 2 7,75 30 3 7,75 31 3 8,0 45 2 7,75 51 3 7,75 60 2 8,0 66 2 7,75 68 2 8,0 75 3 8,0 100 2 8,0 200 2 10,0 Table 4: Reproduction rate in KID 50 /ml of Vero-MVA and the wild-type MVA in different cell culture systems [log 10 /ml] Cell culture system Vero-MVA (31.Vero-passage) Wild-type MVA (575.
- IL-1 ⁇ Cellular markers Activation of T-helper cells (CD4, CD8, CD25) Increased activation of cytotoxic T-lymphocytes Activation of NK cells Increased activation of NK cells Abortive reproduction in mammalian cells (except BHK cells) Further narrowing of the host spectrum in cell culture systems Cytokine Interferon ⁇ , IL-2, IL-12 Interferon ⁇ and ⁇ , IL-1, 2, 12 Virus titer CEF: 10 9,5 KID 50 /ml Vero cells: 10 4,0 KID 50 /ml CEF: 10 4,5 KID 50 /ml Vero cells: 10 9,5 KID 50 /ml Immune system Reduction of activity of specific immune system Inhanced activity of the unspecific immune system Virulence for humans and animals low none
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present invention relates to new strains of the Modified Vaccinia virus Ankara (MVA) that have a strongly reduced virulence for most mammals, especially humans, but nevertheless grows in cells of a continuous cell line approved for the production of a therapeutic agent such as a vaccine. The invention also relates to a method for producing said adapted MVA strains. The MVA can be used e.g. for parenteral immunization, as a vector system, or in the active or inactivated form as an adjuvant or as a regulator of the unspecific components of the immune system.
- An organism is constantly challenged by infectious agents like bacteria, viruses, fungi or parasites. The immune system prevents the organism from permanent infection caused by these agents by the destruction and elimination of these infectious agents and any toxic molecules produced by them. The immune system can be divided into a specific and an unspecific part although both parts are closely cross linked. The unspecific immune response enables an immediate defense against a wide variety of foreign substances and infectious agents. In contrast, the specific immune response is raised after a lag phase, when the organism is challenged with a substance for the first time. However, the specific immune response is highly efficient. The specific immune response is responsible for the fact that an individual who recovers from a specific infection is protected against this specific infection but still susceptible for other infectious diseases. In general, a second infection with the same or a very similar infectious agent causes much milder symptoms or no symptoms at all. The immunity persists for a long time, in some cases even lifelong. This immunological memory is used for vaccination, where the organism is challenged with a harmless or inactivated form of the infectious agent to induce a specific immunity. Sometimes adjuvants are incorporated into vaccines to enhance the specific immune response.
- Much of the knowledge about infectious diseases and immunity is contributed by studies of smallpox. The disease is caused by the variola virus, a member of the genus of Orthopox viruses. Nearly two centuries ago, prophylactic inoculations with cowpox was initiated resulting in the immunization against smallpox. Later immunization was performed with the Vaccinia virus. In the early 1950s, many of the industrialized countries had eliminated endemic smallpox by using vaccination with Vaccinia virus. However, smallpox vaccination with this Vaccinia virus resulted occasionally in serious complications, such as postvaccinal encephalitis, generalized Vaccinia or contact infection.
- A new vaccine that does not show these complications was developed by Anton Mayr. The pox vaccine consists of the pox virus Modified Vaccinia Virus Ankara (MVA) and was used for parenteral vaccination against smallpox in about 150 000 vaccinations without causing any complications related to the vaccination. Even children with immunologic deficiencies did not show serious side effects. The MVA was obtained by mutation and selection of the original vaccina virus Ankara after 575 passages in chicken embryo fibroblast cultures. The safety of this MVA is reflected by biological, chemical and physical characteristics. MVA has a reduced molecular weight, six deletions in the genome, and is highly attenuated for mammalian cells, i.e. DNA and protein is synthesized but virtually no viral particles are produced. The Modified Vaccina virus Ankara developed by Anton Mayr was deposited at the European Collection of Cell Cultures (ECACC), Salisbury, UK, under depository No. V 94012707.
- The vaccination against smallpox was highly successful. In 1979, the World Health Organization declared the eradication of smallpox. Accordingly, the mass vaccination of children was discontinued and only laboratory workers and members of the armed forces of some countries are vaccinated.
- With the eradication of smallpox, the predominant cause of pox infection in humans was removed. However, some non-human poxviruses have reduced host specificity, i.e. they cause infections not only in their typical host (e.g. for cowpox the cow), but also in other animals, (e.g. rats and cats). Humans can be infected by this route as well. Since parts of the population are no longer immune against smallpox, orthopox infections of animal species can be dangerous for them. Domestic animals are the main source of infection for humans. Accordingly, the vaccination of domestic animals against orthopoxviruses is of increasing importance. In addition, the MVA may be of significance as a vector for gene therapy, i.e. to transfer nucleic acid sequences into a target cell where they are expressed.
- Further, empirically obtained results have been reported showing that patients who were immunized and protected against smallpox also rapidly recovered from other infections and diseases. It was deduced from these findings that poxviruses or certain structural components of these viruses can positively influence the organism's ability to resist infections and tumours, on a non-specific level. Since these non-specific healing processes commence immediately after vaccination and hence 5 to 7 days before the specific immunity conferred by vaccination develops, as well as parallel thereto, these non-specific consequences of a prophylactic immunization was designated as "paraspecific". Accordingly, medicaments produced specifically to exploit such paraspecific effects are known as "paramunity inducers". Multipotent paramunity inducers based on combination of poxvirus components derived from various poxviruses with paramunizing properties have been developed (see WO 95/22978).
- The host ranges of MVA and of the parental Ankara strain were compared in chicken embryo fibroblast (CEF) cells and 15 permanent cell lines (Carroll, M.W. and Moss, B. (1997): Virology 238, 198-211). The cells were grouped into three categories: permissive, semipermissive, and nonpermissive. It was found that baby hamster kidney (BHK) cells supported MVA growth and that only in this cell line did the virus yield approach that occurring in primary CEF cells. Other cell lines were non-permissive or allowed only limited MVA replication. The permissive BHK cell line was shown to be also competent for constructing and propagating recombinant MVA, providing an alternative to primary CEF. These results and findings, respectively, were confirmed by further investigations (see also Drexler, I. et al. (1998), Journal of General Virology 79, 347-352).
- However, for a logarithmic reproduction of the MVA, cell cultures of primary or secondary chicken embryo fibroblasts are used. The cells are obtained from chicken eggs that are incubated for 10 to 12 days. Since eggs are subjected to a biological variability, the cells obtained for the cell culture system are variable on a cellular level as well. In addition, in a chicken embryo "fibroblast culture" often other cell types such as epithelial cells are found. This variation of the cells also results in variation of viruses produced in chicken embryo fibroblasts. It is therefore difficult to standardize and validate the cell culture system to guarantee a constantly high quality of the MVA produced. Furthermore, contamination of the cell culture system by microorganisms or viruses already present in the incubated eggs can not be completely excluded. When the MVA is grown in virus-contaminated cells, the MVA may recombine with the contaminating virus. Thereby an MVA with new and unpredictable characteristics may be generated. For the production of the virus in large scale in a suspension culture, primary or secondary chicken embryo fibroblasts are also not highly suitable. In addition, the purification and concentration of MVA by ultra gradient centrifugation would be advantageous. However, such purification is difficult, when MVA is cultivated on primary or secondary chicken embryo fibroblast. Finally, an increasing number of patients have developed allergies against chicken egg's albumen. Although the in vitro conditions of the cultivation strongly reduce the allergenic potential, a hazard of an allergic reaction can not be completely excluded.
- In conclusion, on the one hand the MVA can only be efficiently grown in primary or secondary chicken embryo fibroblasts causing a number of disadvantages, however, on the other hand the save application of the MVA in humans has been shown by its large-scale application as a vaccine.
- It is an object of the present invention to provide conditions for the production of homogeneous virus particles of the MVA. Additionally, said conditions should allow an easy and large-scale production of the MVA.
- The invention inter alia comprises the following, alone or in combination:
- A modified vaccinia virus Ankara (MVA) adapted for growing in cells of a Vero cell line, obtainable by a process comprising the steps of: a) infecting cells of the Vero cell line with a wild-type MVA, preferably with the MVA deposited at the European Collection of Cell Culture (ECACC), Salisbury, UK, under depositary No. V94012707; b) harvesting the viral particles produced by the infected cells of said cell line; and, c) infecting fresh cells of the Vero cell line with the newly produced viruses and harvesting the virus produced from said cells, wherein step c) is repeated until the Output/Input ratio of the virus titer is greater than 1.
- The MVA as above, wherein said cell line is the Vero cell line ATCC No. CCL-81.
- The MVA as above, deposited at the European Collection of Cell Cultures (ECACC), Salisbury, UK under depositary No. 99101431 and/or a modified vaccinia virus Ankara adapted for growing in Vero cells at a rate which is the same as the growth rate of the deposited strain, but which carries at least one difference in its genome.
- The MVA as above, deposited at the European Collection of Cell Cultures (ECACC), Salisbury, UK, under depositary number 01021411 and/or a modified vaccinia virus Ankara adapted for growing in Vero cells at a rate which is the same as the growth rate of the deposited strain, but which carries at least one difference in its genome.
- The MVA as above, comprising at least one heterologous nucleic acid sequence.
- The MVA as above, wherein the heterologous nucleic acid sequence codes for a therapeutic protein and/or an antigenic determinant.
- A host cell infected in vitro or ex vivo by the above described MVA.
- A composition, preferably a pharmaceutical composition, comprising the above described MVA and/or the DNA of the MVA.
- The composition described above, wherein the composition is a vaccine.
- The composition described above for the immunization of a living animal body including a human.
- The composition as above for the immunization against an Orthopox infection.
- The composition as above for the immunization of cats against a cat pox infection, mice against ectromelia infection and/or camels against camelpox infection.
- The composition described above, wherein the MVA is an activator, suppressor and/or stabilizer of the immune system.
- A composition, preferably a pharmaceutical composition, comprising the above described MVA and/or the DNA of the MVA as an adjuvant.
- A composition, preferably a pharmaceutical composition, comprising the above described recombinant MVA and/or the DNA of the recombinant MVA for use in gene therapy.
- A method for introducing a homologous and/or heterologous nucleic acid sequence into a target cell in vitro or ex vivo comprising infecting the target cell with the above described MVA and/or DNA of the MVA.
- A method for obtaining an MVA strain as described above, comprising the steps of: a) infecting cells of a Vero cell line with a wild-type MVA, preferably the MVA deposited at ECACC under depository No. V 94012707, b) harvesting the viruses obtained from the cells infected according to step a), c) infecting fresh cells of the Vero cell line with the newly produced viruses and harvesting the virus produced from said cells, wherein step c) is repeated until the Output/Input ratio in viral titer is greater than 1.
- A method for producing viral particles of the above described MVA, comprising the steps of: a) cultivating the cells of a cell line, in which the MVA replicates under suitable conditions, b) infecting said cell line with the MVA as described above, and c) harvesting the viral particles produced by said cells.
- A method for producing a nucleic acid sequence, peptide and/or polypeptide, comprising the steps of: a) infecting a host cell with the above described recombinant MVA, b) cultivating the infected host cell under suitable conditions, and, optionally, c) isolating and/or enriching the nucleic acid sequence, peptide and/or protein produced by said host cell.
- Use of the above described MVA for producing a pharmaceutical composition for the treatment or prevention of a disease or disorder responsive to said MVA.
- Use of the above described MVA for producing a vaccine for the immunization of a living animal body including a human.
- Use of the above described MVA for producing an activator, suppressor and/or stabilizer of the unspecific immune system.
- Use of the above described MVA for the manufacture of an adjuvant.
- To achieve the foregoing and other objects, the present invention provides an MVA strain that is adapted for growing in cells of a continuous cell line, namely in a Vero cell line, said cell line being approved for the production of a therapeutic agent.
- According to the present invention, for the first time an efficient and large-scale production of MVA is possible. Since cells of a continuous cell line are homogeneous and their characteristics are stable the MVA harvested from Vero cell lines is also homogeneous with highly predictable characteristics. Furthermore, the risk of contamination by microorganisms can be controlled and contamination of the MVA preparation by proteins of the chicken egg as found when cultivating MVA on chicken embryo fibroblasts - can be excluded. The handling of a permanent cell line is convenient and thus highly suitable for industrial application.
- By using a Vero cell line, the MVA is adapted for growing in cells of a mammalian cell line, which is approved for the production of a vaccine. It has been surprisingly found that the MVA adapted to this mammalian cell line still has a reduced virulence for humans and also for a wide range of other mammals. Accordingly, the MVA is highly attenuated i.e. DNA and protein is synthesized but virtually no viral particles are produced, resulting in a virtually eliminated disease-causing capacity. Hence, the MVA according to the present invention is also highly suitable as a vaccine for humans and for a wide range of mammals. Accordingly, the MVA is especially applicable in the veterinary field.
- Furthermore, a method to obtain an MVA strain according to the present invention is provided. According to this embodiment of the invention, cells of a Vero cell line, are infected with the wild-type MVA. Preferably a high multiplicity of infection (MOI), i.e. a high number of viruses per cell is used for this infection. Then, the viruses are harvested and fresh cells of the same cell line are infected with the newly produced viruses. Said process is repeated (serial passaging) until the MVA is adapted to said cell line. Adaptation is reached, when 72h post infection, the virus titer is at least 1· to 9-fold, preferably 10· to 99-fold, more preferably 100- to 106-fold, and most preferably more than 107· to 1010·fold increased compared to the input virus titer. The adaptation is reached after a limited number of passages.
- "Adapted for growing" means that the amount of virus produced from an infection (Output) is increased compared to the amount of virus originally used to infect the cells (Input). In this case the Output/Input ratio is greater than 1.
- "Derivative" of the MVA deposited at ECACC, Salisbury, UK, under the depository number 99101431 and/or accession number 01021411 means an MVA which is adapted for growing in Vero cells at a rate, which is essentially the same as the growth rate of the deposited strain but carries at least one difference in its genome compared to the deposited strain.
- The term "immune system" basically describes a complex involved in the defence of the organism against foreign substances and microorganisms. It is divided into a cellular part comprising several cell types, such as e.g. lymphocytes and other cells derived from white blood cells, and a humoral part comprising peptides and proteins such as antibodies, complement factors, and cytokins.
- The term "immune response" describes the reaction of the immune system, when a foreign substance or microorganism enters the organism. Generally, the immune response is divided into a specific and an unspecific reaction although both are closely cross linked. The unspecific immune response is regarded as the immediate defence against a wide variety of foreign substances and infectious agents. The specific immune response can be characterised as a highly efficient defence mechanism of the organism against a foreign substance which is raised against said substance after a lag phase and highly specific for said substance. The specific immune response is responsible for the phenomenon that an individual who has recovered from a specific infection is protected against this specific infection in future. "Activator of the immune system" means any substance capable of provoking or enhancing an immune response.
- "Suppressor of the immune system" means any substance capable of reducing or inhibiting an immune response.
- "Stabilizer of the immune system" means any substance capable of keeping the immune response on a constant level.
- The inventor provides two preferred MVA strains that are adapted to an African green monkey cell line, called Vero cell line (ATCC No. CCL-81). The MVA-strain, which was passaged 100-times in Vero cells was called "Vero-MVA" and deposited at the European Collection of Cell Cultures, Salisbury, UK under depositary No. 99101431. The MVA strain after 200 passages in Vero cells was called "Vero-MVA-200" and deposited at ECACC under accession number 01021411.
- The MVA obtained as described above is further amplified by cultivating the cells of the approved cell line under suitable conditions, infecting cells with the MVA and harvesting the viral particles produced by said cells. Hence the MVA can efficiently and easily be amplified in large-scale. Surprisingly, the MVA of the invention does not show increased virulence in cells other than Vero cells such as human cell lines including HL, HEP-2 or HeLA.
- In another embodiment of the invention, the MVA contains at least one heterologous nucleic acid sequence i.e. a nucleic acid sequence that is not naturally found in the MVA genome (recombinant MVA). Preferably, the heterologous nucleic acid sequence is a gene, more preferably a gene encoding an immunizing protein, and most preferably encoding a protein immunizing against malaria, rabies and/or hepatitis. The expression of said heterologous nucleic acid sequence is preferably under the transciptional control of a vaccinia virus promoter, more preferably of an MVA-own promoter. In a further preferred embodiment of the invention, the heterologous nucleic acid sequence is inserted at a naturally occurring deletion site in the MVA genome (disclosed in PCT/EP96/02926).
- The recombinant MVA is used for the introduction of a nucleic acid sequence into a target cell, said nucleic acid sequence being homologous or heterologous to the target cell. The introduction of a heterologous nucleic acid sequence into a target cell may be used to produce heterologous nucleic acids, peptides and/or polypeptides and/or proteins encoded by said nucleic acid sequence in vitro. This method comprises the infection of a host cell with the recombinant MVA, cultivation of the infected host cell under suitable conditions, and optionally isolation and/or enrichment of the peptide and/or protein produced by said host cell.
- Furthermore, the introduction of a homologous or of a heterologous sequence may be applied for in vitro and in vivo gene therapy. For in vitro and ex vivo gene therapy respectively, cells are isolated from the individual to be treated, transformed with the recombinant MVA and reintroduced into the individual the cells were taken from. For in vivo gene therapy, the recombinant MVA is directly administered to the living animal body including the human body.
- In a preferred embodiment of the invention, the recombinant MVA expresses an antigen or an antigenic epitope. Most preferably, said vector expresses an antigenic determinant from Plasmodium falciparum, Mycobacteria, Herpes virus, Influenza virus, hepatitis, or a human immunodeficiency virus.
- Since the MVA according to the invention is - surprisingly - still highly attenuated, the MVA is ideal to immunize a wide range of mammals including humans. Hence, the present invention also provides a vaccine comprising the MVA for the immunization of a living animal body including a human against pox infections, preferably orthopox infections. The vaccine may contain in addition to the MVA one or more additives such as an antibiotic, a preservative, or a stabilizer. The vaccine is especially applicable in the veterinary field, e.g. for the immunization of animals against orthopox infections such as cats against cat pox, mice against ectromelia or camels against camelpox. The immunization is preferably performed parenterally.
- The immunizing effect of an antigenic determinant in a vaccine is often enhanced by the addition of a so-called adjuvant. An adjuvant co-stimulates the immune system in an unspecific manner causing a stronger specific immune reaction against the antigenic determinant of the vaccine. According to another embodiment of the invention, the MVA is used as an adjuvant, to co-stimulate the immune response against the antigenic determinant of a vaccine. In this case it is preferred that the MVA is inactivated. The inactivation of the MVA may be performed e.g. by heat or chemicals. Preferably, the MVA is inactivated by β-propiolacton. According to this embodiment of the invention, the inactivated MVA may be added to vaccines against numerous infectious diseases to increase the immunity against this disease.
- In case of an infection, the immune, the nervous, the hormonal and the vascular system of an individual work closely together. These interactions can be regulated by elements of the unspecific immune system e.g. cytokines such as interferons and interleukins. Pox viruses can influence the regulation of the immune system (Swiss Vet 11/99, 13-17). Hence, in a further embodiment of the invention, the MVA and preferably the inactivated MVA is used in mammals including humans to regulate the cellular and humoral elements of the unspecific (innate) immune system. Preferably the MVA is used as a bioregulator, wherein dysfunctions of the immune system are eliminated and the body's own defence mechanisms are activated, stabilized and/or suppressed. Most preferably, the MVA is used as a bioregulator in case of a viral infection e.g. with herpes, hepatitis B or C virus, in case of a chronic inflammatory disease and/or to support tumor therapy. The MVA may also be used to stabilize the immune system in a situation of increased susceptibility against infections such as in the case of stress or in neonatals. The active and/or preferably the inactivated MVA can be applied systemically e.g. intramuscularly and/or locally e.g. through mucous membranes and/or skin.
- In conclusion, the present invention provides MVA strains that can in general be used for the same applications as the wild-type MVA, but eliminate the problems caused by the amplification of the wild-type MVA in chicken embryo fibroblasts.
- The following examples will further illustrate the present invention. It will be well understood by a person skilled in the art that the provided examples in no way may be interpreted in a way that limits the applicability of the technology provided by the present invention to these examples.
- The by Anton Mayr developed wild-type MVA that is a modified Vaccina virus Ankara was deposited at ECACC under depository No. V 94012707. The wild-type MVA was adapted to grow in Vero-cells by serial passaging of the virus in Vero cells (Table 1). The cell clone ATCC-No. CCL-81 of the stationary Vero cell line (WHO seed stock ECACC No. 88020401) was used in the passage No. 148 to 165 (WHO seed lot, Master and Working Bank). The cells were propagated in a medium consisting of Earle's MEM (ICN), pH 7,4 - 7,6, and 5% of the serum substitute BMS (Biochrom). According to a technique known by people skilled in the art, always the same cells of the working bank were seeded by splitting the cells 1:2 to 1:4. The medium contained approximately 250 000 cells per ml. The cells were respectively propagated in tubes (2ml), Roux dishes (100ml), and plastic dishes (6 and 40ml respectively). In general, the cells formed a confluent monolayer after 16 to 24h. Afterwards, the medium was replaced by plain Earle's MEM without any additives.
- For the adaptation of the wild-type MVA a tube culture system was used. The results of the passages are summarized in Table 1 and 2. The Vero cells were infected by 10 MOI (multiplicity of infection) of the wild-type MVA, i.e. in average, 10 viral particles per Vero cell. The wild-type MVA to start with was a genetically homogeneous, plaque-purified MVA after 575 passages in chicken embryo fibroblasts (titer: 107,75 KID50/ml). After 24h, 90% of the Vero cells of the confluent monolayer were destroyed by toxic processes (50% by toxicity, 40% by lysis). The medium plus the cell dedritus after freezing and thawing of the cells, containing the produced viruses, was harvested and 0,2ml of this mixture were seeded on the monolayer of Vero cells in the culture tubes (2nd passage). This procedure was repeated 200 times. After the third passage, no toxic effect was observed any more, whereas a mild cytopathic effect (CPE) characterized by rounding of the cells and lysis in a period of 4 to 6 days post infection (p.inf.) was seen. The virus titer was 101,0 KID50/ml. It was concluded that the proliferation of the MVA in Vero cells had started although very inefficiently. After the fifth passage, a typical CPE was observed which was completed after 4 to 5 days p.inf. The virus titer increased from 101,0 KID50/ml after the third passage to 104,0 KID50/ml after the fifth passage. Hence, the virus amplified more efficiently in Vero cells. In the passages No. 5 to 11, a complete CPE was observed more and more early and the virus titer increased with every passage. At passage No. 11, a plateau was reached at 107,5 KID50/ml. Accordingly, after eleven passages the adaptation of the MVA to Vero cells was achieved. In the following 30 additional passages, the results were for all passages the same and highly reproducible: The CPE began already 24h p.inf. and all cells were affected after three days p. inf. At that time, 20% of the Vero cells were rounded and 80% were lysed. After three days p.inf., the virus titer was always about 107,75 KID50/ml. After the fifteenth passage, the viruses were always harvested after two to three days p.inf., and only 1 MOI instead of 10 MOI were used to infect the cells (Table 2). In the following additional passages the growth characteristics of the MVA changed only slightly. Remarkably, the optimum virus titer further increased and reached 1010 KID50/ml at passage 200.
- In conclusion, the virus grows reproducibly in an exponential manner in Vero cells. Said growth characteristic is surprisingly different to the characteristics of the wild-type MVA. Accordingly, a new strain of the MVA was obtained by the serial passaging. Said new strain was called "Vero-MVA" and after passage 200 in vero cells "Vero-MVA-200".
- The Vero-MVA and Vero-MVA-200 were cultivated in larger quantities. For storage, the Vero-MVA was concentrated by centrifugation, resuspended in 2,5 % polygeline and lyophilized in vials of 2ml. The titer after lyophilization was still at least 108,5 KID50/ml. The lyophilized Vero-MVA and Vero-MVA-200 was checked for contamination and toxicity and stored at +4°C.
- The biological characteristics of the Vero-MVA (passage 100) and Vero-MVA-200 (passage 200) were compared with the characteristics of the wild-type MVA (Table 3 and Table 5). Thereby, the techniques known by the skilled practitioner were applied. The inventors showed that neither the host range of the virus was changed except for the Vero cells, nor the virulence for humans or animals was increased. The Vero-MVA is still characterized by the abortive propagation in non-permissive host cells.
- The principal identity of the viral particles of the Vero-MVA compared to the viral particles of the Elstree strain of the Vaccinia virus was shown by cross reactivity of antibodies raised against the Elstree strain. The Elstree strain is a Vaccinia strain recommended by the WHO for the smallpox vaccination. The polyclonal hyperimmune serum of rabbits raised against the Elstree strain was added to the Vero-MVA. 100 KID50/ml of the Vero MVA were completely neutralized at a dilution of the serum of 1:512. A twofold dilution of the serum was necessary to neutralize the same amount of Vaccinia Elstree strain (1:256). Accordingly, the Vero-MVA can still be efficiently neutralized by Vaccinia immune serum.
- The Vero-MVA, the Vero-MVA-200 and the wild-type MVA were compared by a number of additional tests as indicated in Table 3, 4 and 5. The inventors showed that the virulence of Vero-MVA and Vero-MVA-200 for mammals including humans was not increased compared to the wild-type MVA. It was also shown that the Vero-MVA and Vero-MVA-200 are not contagious or toxic for mammals including humans. Surprisingly, the cell specificity of the Vero-MVA was more or less identical to the specificity of the wild-type MVA except for the Vero cells: The Vero-MVA amplifies nearly as inefficiently in cells of human cell lines (see table 4: HL-, HEP-2-, and HeLa-cells) as the wild-type MVA does. Accordingly, although human cells and cells of African green monkeys are phylogenetically closely related, the Vero-MVA did not gain the ability to amplify in human cells. In other tests, no significant difference were seen either.
- Furthermore, the physical, chemical, and biological characteristics of the wild-type MVA and the Vero-MVA-200 were compared (Table 5). Whereas the wild-type MVA growing in chicken embryo fibroblast cell cultures has three deletions in the left inverted terminal region, the Vero-MVA-200 has four deletions in the left terminal region compared to the genome of the pox virus as originally isolated in Ankara. Hence, passaging of the wild-type MVA in Vero cells resulted in an additional deletion.
- The Vero-MVA was used to immunize domestic animals against Orthopox infections. The serum of the animals was collected and a neutralization test was performed. The inventors showed that the animals produced antibodies in high titers. The antibody titers were stable over a period of at least 111 days. It was also shown that the antibodies were able to neutralize in vitro viral particles of the MVA in a plaque-reduction test. In conclusion, the Vero-MVA can be used as a vaccine against Orthopox infections in domestic animals and in humans.
Table 1: Adaptation of the MVA to Vero cells Passage No. Cell culture Highest virus titer [log10/ml] Result Conclusion 1 toxic effect after 24h 2,0 Rests of the virus seeded Blind passages 3 No toxicity, moderate CPE after 4-6 days 1,0 Rests of the virus seeded? Begin of the virus reproduction Phenomenon of zones and cytokine production 5 typical CPE completed after 4-5 days 4,0 Increasing virus reproduction 11 CPE completed after 3 days 7,5 Logarithmic virus reproduction Adaptation successful 12-42* CPE begins after 24h, completed after 3 days 7,75 Reproducible virus reproduction Vero-MVA 43-100* CPE begins after 24h, completed after 3 days 8,0 Repoducible virus reproduction Vero MVA 100-200* CPE begins after 24h, completed after 3 days 10,0 Repoducible virus reproduction Results in Vero-MVA-200 * Only 1 MOI instead of 10 MOI are seeded after the eleventh passage. Table 2: Change of the virus titers during the adaptation of the MVA to Vero cells Passage No. Harvested after [days p.inf.] Titer per ml [log10/ml] 1 1 <2,0 2 3 2,0 3 5 1,0 5 5 4,0 8 4 6,5 11 3 7,5 18 2 8,0 19 2 7,75 20 3 8,0 25 2 7,75 29 2 7,75 30 3 7,75 31 3 8,0 45 2 7,75 51 3 7,75 60 2 8,0 66 2 7,75 68 2 8,0 75 3 8,0 100 2 8,0 200 2 10,0 Table 4: Reproduction rate in KID 50 /ml of Vero-MVA and the wild-type MVA in different cell culture systems [log 10 /ml] Cell culture system Vero-MVA (31.Vero-passage) Wild-type MVA (575. passage in primary chicken embryo fibroblasts) 1) Vero (African green monkey kidney cells) 8,0 4,5 Primary chicken embryo fibroblasts 4,5 8,5 1,2) HL (human lung) 3,0 2,5 1,2) HEP-2 (human epidermoid carcinoma) 3,0 2,5 1,2) HeLA (human cervix carcinoma 2,75 2,75 1,2) BHK (hamster kidney cells) 5,75 5,25 1,2) MDBK (bovine kidney cells) 3,5 3,5 1,2) PK-15 (porcine kidney cells) 3,25 3,5 1) Continuous cell line derived from the tissue and species indicated in brackets. 2) Cell lines obtained from the collection of the institute of medical microbiology in Munich, Germany. Table 5: Comparison of the wild-type MVA (572. passage in chicken embryo fibroblasts (CEF)) with Vero-MVA-200 (200. passage in vero cells) Marker Wild-type MVA Vero-MVA-200 Genetic markers (comparison with pox virus strain as isolated in Ankara) 3 deletions in the left terminal region (inverted terminal repeat) 4 deletions in the left terminal region Genome size reduced from 208 to 178 kb Further reduction of the genome size to 172kb Loss of 15% of the molecular weight of the original genome Loss of 20% of the molecular weight of the original genome Loss of the interferon receptor Additional loss of receptors e.g. for IL-1β Cellular markers Activation of T-helper cells (CD4, CD8, CD25) Increased activation of cytotoxic T-lymphocytes Activation of NK cells Increased activation of NK cells Abortive reproduction in mammalian cells (except BHK cells) Further narrowing of the host spectrum in cell culture systems Cytokine Interferon α, IL-2, IL-12 Interferon α and γ , IL-1, 2, 12 Virus titer CEF: 109,5 KID50/ml Vero cells: 104,0 KID50/ml CEF: 104,5 KID50/ml Vero cells: 109,5 KID50/ml Immune system Reduction of activity of specific immune system Inhanced activity of the unspecific immune system Virulence for humans and animals low none
Claims (23)
- A modified vaccinia virus Ankara (MVA) adapted for growing in cells of a Vero cell line, obtainable by a process comprising the steps of:a) infecting cells of the Vero cell line with a wild-type MVA, preferably with the MVA deposited at the European Collection of Cell Culture (ECACC), Salisbury, UK, under depositary No. V94012707;b) harvesting the viral particles produced by the infected cells of said cell line; and,c) infecting fresh cells of the Vero cell line with the newly produced viruses and harvesting the virus produced from said cells, wherein step c) is repeated until the Output/Input ratio of the virus titer is greater than 1.
- The MVA according to claim 1, wherein said cell line is Vero cell line ATCC No. CCL-81.
- The MVA according to claim 1 or 2, deposited at the European Collection of Cell Culture (ECACC), Salisbury, UK, under depositary No. 99101431 and/or a modified vaccinia virus Ankara adapted for growing in Vero cells at a rate which is the same as the growth rate of the deposited strain, but which carries at least one difference in its genome.
- The MVA according to claim 1 or 2, deposited at the European Collection of Cell Cultures (ECACC), Salisbury, UK, under depositary No. 01021411 and/or a modified vaccinia virus Ankara adapted for growing in Vero cells at a rate which is the same as the growth rate of the deposited strain, but which carries at least one difference in its genome.
- The MVA according to any of the preceding claims 1 to 4, comprising at least one heterologous nucleic acid sequence.
- The MVA according to claim 5, wherein the heterologous nucleic acid sequence codes for a therapeutic protein and/or an antigenic determinant.
- A host cell infected in vitro or ex vivo by an MVA virus according to any of the preceding claims 1 to 6.
- A composition, preferably a pharmaceutical composition, comprising the MVA and/or DNA of the MVA according to any of the preceding claims 1 to 6.
- The composition according to claim 8, wherein the composition is a vaccine.
- The composition according to claim 9 for the immunization of a living animal body including a human.
- The composition according to claim 9 or 10 for the immunization against an Orthopox infection.
- The composition according to claims 9 to 11 for the immunization of cats against a cat pox infection, mice against ectromelia infection and/or camels against camel pox infection.
- The compostion according to claim 8, wherein the MVA is an activator, suppressor and/or stabilizer of the immune system.
- A composition, preferably a pharmaceutical composition, comprising the MVA and/or DNA of the MVA according to any of the preceding claims 1 to 6 as an adjuvant.
- A composition, preferably a pharmaceutical composition, comprising the recombinant MVA and/or DNA of the recombinant MVA according to claim 5 or 6 for use in gene therapy.
- A method for introducing a homologous and/or heterologous nucleic acid sequence into a target cell in vitro or ex vivo comprising infecting the target cell with the MVA and/or DNA of the MVA according to claim 5 or 6.
- A method for obtaining an MVA strain according to any of the preceding claims 1 to 6, comprising the steps of:a) infecting cells of a Vero cell line with a wild-type MVA, preferably with the MVA deposited at ECACC under depositary No. V 94012707;b) harvesting the viruses obtained from the cells infected according to step a);c) infecting fresh cells of the Vero cell line with the newly produced viruses and harvesting the virus produced from said cells, wherein step c) is repeated until the Output/Input ratio in viral titer is greater than 1.
- A method for producing viral particles of the MVA according to any of the preceding claims 1 to 6, comprising the steps of:a) cultivating the cells of a cell line, in which the MVA replicates under suitable conditions;b) infecting said cell line with the MVA according to any of the preceding claims 1 to 6, andc) harvesting the viral particles produced by said cells.
- A method for producing a nucleic acid sequence, peptide and/or polypeptide comprising the steps ofa) infecting a host cell with the recombinant MVA according to claims 5 or 6;b) cultivating the infected host cell under suitable conditions; and, optionallyc) isolating and/or enriching the nucleic acid sequence, peptide and/or protein produced by said host cell.
- Use of the MVA according to any of the preceding claims 1 to 6 for producing a pharmaceutical composition for the treatment or prevention of a disease or disorder responsive to said MVA.
- Use of the MVA according to any of the preceding claims 1 to 6 for producing a vaccine for the immunization of a living animal body including a human.
- Use of the MVA according to any of the preceding claims 1 to 6 for producing an activator, suppressor and/or stabilizer of the immune system.
- Use of the MVA according to any of the preceding claims 1 to 6 for the manufacture of an adjuvant.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK200000410 | 2000-03-14 | ||
DKPA200000410 | 2000-03-14 | ||
PCT/EP2001/002703 WO2001068820A1 (en) | 2000-03-14 | 2001-03-10 | Altered strain of the modified vaccinia virus ankara (mva) |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1263936A1 EP1263936A1 (en) | 2002-12-11 |
EP1263936B1 true EP1263936B1 (en) | 2005-09-21 |
Family
ID=8159327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01931508A Expired - Lifetime EP1263936B1 (en) | 2000-03-14 | 2001-03-10 | Altered strain of the modified vaccinia virus ankara (mva) |
Country Status (25)
Country | Link |
---|---|
US (1) | US6682743B2 (en) |
EP (1) | EP1263936B1 (en) |
JP (1) | JP4759201B2 (en) |
KR (1) | KR100880765B1 (en) |
CN (1) | CN1291012C (en) |
AT (1) | ATE305030T1 (en) |
AU (1) | AU780696B2 (en) |
BR (1) | BR0109158A (en) |
CA (1) | CA2397675C (en) |
CZ (1) | CZ293690B6 (en) |
DE (1) | DE60113512T2 (en) |
DK (1) | DK1263936T3 (en) |
EE (1) | EE05633B1 (en) |
ES (1) | ES2249430T3 (en) |
HK (1) | HK1052725B (en) |
HU (1) | HU228691B1 (en) |
IL (3) | IL150736A0 (en) |
MX (1) | MXPA02008873A (en) |
NO (1) | NO20024246L (en) |
NZ (1) | NZ521270A (en) |
PL (1) | PL205922B1 (en) |
RU (1) | RU2280075C2 (en) |
SI (1) | SI1263936T1 (en) |
UA (1) | UA84388C2 (en) |
WO (1) | WO2001068820A1 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
EE05680B1 (en) | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Modified vaccine virus, its preparation and use, pharmaceutical composition containing it and vaccine |
US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
EP1357127A1 (en) * | 2002-04-10 | 2003-10-29 | Immusystems GmbH | Hepatitis c virus epitopes specific for cd4+ t-cell lymphocytes |
PL220781B1 (en) * | 2002-04-19 | 2016-01-29 | Bavarian Nordic As | Modified vaccinia virus ankara for the vaccination of neonates |
PT1407033E (en) * | 2002-05-16 | 2006-05-31 | Bavarian Nordic As | INTERGENIC REGIONS AS INSERTION SITES IN VACCINIA ANKARA (MVA) MODIFIED VIRUS GENOME |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
KR101044538B1 (en) * | 2002-09-05 | 2011-06-27 | 버베리안 노딕 에이/에스 | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
CA2515890C (en) | 2003-02-20 | 2013-09-17 | Therion Biologics Corporation | Novel insertion sites in pox vectors |
EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
US7423155B2 (en) | 2003-11-14 | 2008-09-09 | 3M Innovative Properties Company | N-sulfonyldicarboximide containing tethering compounds |
DK1845164T3 (en) * | 2003-11-24 | 2010-09-20 | Bavarian Nordic As | Promotes for expression in modified vaccinia virus ankara |
DE102004003572A1 (en) * | 2004-01-23 | 2005-08-18 | Bavarian Nordic A/S | Monoparamunity inducers based on attenuated rabbit myxomaviruses |
US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
US7607323B1 (en) | 2007-10-16 | 2009-10-27 | Hall Charles F | Curl resistant shirt collar and method of fabricating same |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
US9005632B2 (en) | 2009-11-20 | 2015-04-14 | Takeda Vaccines, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains |
WO2011063359A1 (en) | 2009-11-20 | 2011-05-26 | Inviragen, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs |
US20110159031A1 (en) * | 2009-12-22 | 2011-06-30 | Baxter International Inc. | Vaccine to Influenza A Virus |
WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
DE102013004595A1 (en) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV vaccines |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
JP7060324B2 (en) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | Combination therapy with neoantigen vaccine |
US20170021009A1 (en) * | 2014-03-10 | 2017-01-26 | Arizona Board Of Regents On Behalf Of Arizona State | Heat Inactivated Poxvirus Improves Vaccination Results |
EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
NL2014148B1 (en) | 2015-01-16 | 2017-01-05 | Univ Erasmus Med Ct Rotterdam | Combination vaccine for camelids. |
KR20170138996A (en) * | 2015-02-25 | 2017-12-18 | 메모리얼 슬로안-케터링 캔서 센터 | Use of an inactivated non-replicative modified vaccinia virus anchora as a single immunotherapy for solid tumors or in combination with an immuno checkpoint blocking agent |
TWI806815B (en) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | Shared gata3-related tumor-specific neoantigens |
TW202241500A (en) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | Formulations for neoplasia vaccines and methods of preparing thereof |
FR3042121A1 (en) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | ANTI-TUMOR COMPOSITION |
US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
KR102658198B1 (en) | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | Stable virus-containing composition |
CA3081436A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
WO2020051766A1 (en) | 2018-09-11 | 2020-03-19 | 上海市公共卫生临床中心 | Immunogen for broad-spectrum influenza vaccine and application thereof |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
IL308018A (en) | 2021-04-30 | 2023-12-01 | Kalivir Immunotherapeutics Inc | Oncolytic viruses for modified mhc expression |
WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
WO2023220283A1 (en) | 2022-05-12 | 2023-11-16 | Pellis Therapeutics, Inc. | Poxvirus adjuvant for t-cell vaccination |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
DE4405841C1 (en) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotent non-specific immunity inducers based on combinations of poxvirus components, processes for their preparation and their use as pharmaceuticals |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6808706B1 (en) * | 1997-10-15 | 2004-10-26 | Asaki Kasei Pharma Corporation | Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution |
-
2001
- 2001-03-10 EP EP01931508A patent/EP1263936B1/en not_active Expired - Lifetime
- 2001-03-10 WO PCT/EP2001/002703 patent/WO2001068820A1/en active Application Filing
- 2001-03-10 UA UA2002097453A patent/UA84388C2/en unknown
- 2001-03-10 KR KR1020027012058A patent/KR100880765B1/en not_active IP Right Cessation
- 2001-03-10 US US10/204,782 patent/US6682743B2/en not_active Expired - Fee Related
- 2001-03-10 CA CA2397675A patent/CA2397675C/en not_active Expired - Fee Related
- 2001-03-10 MX MXPA02008873A patent/MXPA02008873A/en active IP Right Grant
- 2001-03-10 NZ NZ521270A patent/NZ521270A/en not_active IP Right Cessation
- 2001-03-10 AU AU58269/01A patent/AU780696B2/en not_active Ceased
- 2001-03-10 SI SI200130452T patent/SI1263936T1/en unknown
- 2001-03-10 PL PL357378A patent/PL205922B1/en not_active IP Right Cessation
- 2001-03-10 CN CNB018064949A patent/CN1291012C/en not_active Expired - Fee Related
- 2001-03-10 JP JP2001567304A patent/JP4759201B2/en not_active Expired - Fee Related
- 2001-03-10 DK DK01931508T patent/DK1263936T3/en active
- 2001-03-10 HU HU0300120A patent/HU228691B1/en not_active IP Right Cessation
- 2001-03-10 RU RU2002124622/13A patent/RU2280075C2/en not_active IP Right Cessation
- 2001-03-10 IL IL15073601A patent/IL150736A0/en active IP Right Grant
- 2001-03-10 AT AT01931508T patent/ATE305030T1/en active
- 2001-03-10 EE EEP200200507A patent/EE05633B1/en not_active IP Right Cessation
- 2001-03-10 BR BR0109158-1A patent/BR0109158A/en not_active Application Discontinuation
- 2001-03-10 DE DE60113512T patent/DE60113512T2/en not_active Expired - Lifetime
- 2001-03-10 CZ CZ20023061A patent/CZ293690B6/en not_active IP Right Cessation
- 2001-03-10 ES ES01931508T patent/ES2249430T3/en not_active Expired - Lifetime
-
2002
- 2002-07-15 IL IL150736A patent/IL150736A/en not_active IP Right Cessation
- 2002-09-05 NO NO20024246A patent/NO20024246L/en not_active Application Discontinuation
-
2003
- 2003-06-30 HK HK03104648.5A patent/HK1052725B/en not_active IP Right Cessation
-
2008
- 2008-01-08 IL IL188667A patent/IL188667A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1263936B1 (en) | Altered strain of the modified vaccinia virus ankara (mva) | |
US7897156B2 (en) | Modified vaccinia virus ankara for the vaccination of neonates | |
US8372622B2 (en) | Modified vaccinia virus ankara for the vaccination of neonates | |
US7097842B2 (en) | Modified vaccinia virus ankara for the vaccination of neonates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020910 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20020910;LT PAYMENT 20020910;LV PAYMENT 20020910;MK PAYMENT 20020910;RO PAYMENT 20020910;SI PAYMENT 20020910 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAVARIAN NORDIC A/S |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MAYR, ANTON, PROF.DR.DR.H.C.MULT. |
|
17Q | First examination report despatched |
Effective date: 20040402 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAVARIAN NORDIC A/S |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60113512 Country of ref document: DE Date of ref document: 20051027 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SUSI PRYDE-HAENI BSC |
|
REF | Corresponds to: |
Ref document number: 60113512 Country of ref document: DE Date of ref document: 20060202 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20050403826 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2249430 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20060622 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20120207 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20120213 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20130306 Year of fee payment: 13 Ref country code: IE Payment date: 20130312 Year of fee payment: 13 Ref country code: FI Payment date: 20130312 Year of fee payment: 13 Ref country code: FR Payment date: 20130325 Year of fee payment: 13 Ref country code: SE Payment date: 20130312 Year of fee payment: 13 Ref country code: DK Payment date: 20130312 Year of fee payment: 13 Ref country code: DE Payment date: 20130306 Year of fee payment: 13 Ref country code: LU Payment date: 20130306 Year of fee payment: 13 Ref country code: ES Payment date: 20130313 Year of fee payment: 13 Ref country code: CH Payment date: 20130312 Year of fee payment: 13 Ref country code: MC Payment date: 20130128 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20130215 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20130205 Year of fee payment: 13 Ref country code: AT Payment date: 20130226 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20130312 Year of fee payment: 13 Ref country code: CY Payment date: 20130306 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20130309 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20140910 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60113512 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20140331 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20141001 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM9D Effective date: 20140310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140310 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140310 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140310 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 305030 Country of ref document: AT Kind code of ref document: T Effective date: 20140310 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20140310 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20050403826 Country of ref document: GR Effective date: 20141002 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140311 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20141128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140910 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A Ref country code: SI Ref legal event code: KO00 Effective date: 20141104 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60113512 Country of ref document: DE Effective date: 20141001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141002 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141001 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140310 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140310 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20150731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140311 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140310 |